Enliven Therapeutics (NASDAQ:ELVN) Director Sells 158,795 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Mika Derynck sold 158,795 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the transaction, the director owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. This represents a 64.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics Trading Up 1.0%

Shares of ELVN stock traded up $0.57 during trading hours on Thursday, reaching $60.27. The company’s stock had a trading volume of 1,679,203 shares, compared to its average volume of 962,013. The firm’s 50 day simple moving average is $48.21 and its 200-day simple moving average is $39.53. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Equities analysts predict that Enliven Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Key Enliven Therapeutics News

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: Encouraging clinical progress: Enliven reported positive Phase 1 data for ELVN-001 in chronic myeloid leukemia, including encouraging efficacy and a favorable safety and tolerability profile. The company also said it reached agreement with the FDA on key components of the drug’s Phase 3 trial design. Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
• Positive Sentiment: Strong financial runway: Enliven ended the quarter with $895 million in cash, cash equivalents and marketable securities, which management expects to fund operations into 2030. This reduces near-term financing and dilution concerns for investors.
• Positive Sentiment: Analyst target increases: Goldman Sachs raised its price target from $67 to $80 and maintained a “buy” rating. Stifel Nicolaus also raised its target, from $80 to $82, while maintaining a “buy” rating. The revisions imply substantial upside from the stock’s recent trading level. Goldman Sachs price target update Stifel Nicolaus price target update
• Neutral Sentiment: Director sale: Director Mika K. Derynck sold 158,795 shares for approximately $9.6 million, reducing direct ownership by 64.5%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which may lessen concerns that the sale reflected a negative view of the company, although the transaction could still weigh on sentiment. SEC insider transaction filing
• Negative Sentiment: Quarterly loss exceeded expectations: Enliven reported a second-quarter loss of $0.49 per share, wider than the $0.39 loss analysts expected. The earnings miss contributed to an earlier pullback in the stock and highlights the company’s continuing lack of profitability. Enliven quarterly earnings release

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in ELVN. Vestal Point Capital LP boosted its stake in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after purchasing an additional 2,670,000 shares during the last quarter. Siren L.L.C. acquired a new position in Enliven Therapeutics in the first quarter valued at $29,252,000. Affinity Asset Advisors LLC acquired a new position in Enliven Therapeutics in the first quarter valued at $23,007,000. TCG Crossover Management LLC bought a new stake in Enliven Therapeutics during the second quarter valued at $9,990,000. Finally, Duquesne Family Office LLC grew its holdings in Enliven Therapeutics by 104.6% during the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after acquiring an additional 484,405 shares during the period. Institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

ELVN has been the subject of several research analyst reports. Stifel Nicolaus upped their price target on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday. The Goldman Sachs Group boosted their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. JonesTrading raised their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Mizuho lifted their target price on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $72.67.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.